SightfileU.S. market data from official filings

ARCUS BIOSCIENCES INC COM (RCUS)

Name: ARCUS BIOSCIENCES INC COM (RCUS) — Institutional ownership, SEC filings and insider activity
Creator: Sightfile
License: https://www.sec.gov/privacy#dissemination

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001724521 · EDGAR filings · Updated 2026-07-13

ARCUS BIOSCIENCES INC COM (RCUS) has reported institutional ownership of 94.7%, with 210 institutional managers holding positions valued at $2.57B per the latest 13F reporting period.

Institutional ownership

94.7%

Institutional managers

210

Reported 13F value

$2.57B

Insider activity

56 trans.

−$11.2M net selling

Latest updates

2026-07-13 — Insider transaction reported (Form 4)
2026-07-09 — Notice of proposed sale filed (Form 144)
2026-06-24 — Notice of proposed sale filed (Form 144)
2026-06-24 — Insider transaction reported (Form 4)
2026-06-22 — Notice of proposed sale filed (Form 144)
2026-06-12 — Insider transaction reported (Form 4)

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, ARCUS BIOSCIENCES INC COM has 210 institutional holders and institutional ownership of 94.7%.

Insider activity

Insiders reported 56 transactions (0 buys, 36 sells) across 14 reporting insiders, with a net reported value of −$11.2M.

Related companies

10X GENOMICS INC (TXG) · CATALYST PHARMACEUTICALS INC (CPRX) · BEAM THERAPEUTICS INC (BEAM) · ORUKA THERAPEUTICS INC (ORKA) · IMMUNOME INC (IMNM) · TYRA BIOSCIENCES INC (TYRA)

See full history, cross-references and alerts on Sightfile

Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-13.